Advanced Science-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2023-12-25 ms3000001060797325 来自吉林省

偏重的研究方向：医学基础
经验分享：
8.5 submit
8.20 with editor
8.22 under review
10.17 major review
12.4 R1 submit
12.6 under review
12.22 accept

207 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2022-10-19 ms8000000233807128

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：能源;材料
经验分享：9.10投稿
9.13with editor
9.21送审
10.4大修 2个审稿人主编给了20天时间修改
10.12提交修改稿
10.19接收
17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。

246 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2023-06-02 ms7000001335611101 来自天津

偏重的研究方向：医学;免疫;肿瘤
经验分享：5-24 submitted, 1周了还没变化，后悔死了。

36 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2023-08-12 124a8810m95(暂无昵称) 来自重庆

这个期刊和大CDD比起来怎么样啊？

134 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2022-12-14 ms6000000798925478 来自广东省

12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞

92 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2023-01-17 ms5000001185631738 来自东京都

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：医学;生物材料
经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊

116 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2023-06-18 食野- 来自四川省

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：医学;生物材料
经验分享：6.11 submitted
6.13 with editor
6.18 under review
前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？

111 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2023-04-25 ms9000001428733424 来自北京

偏重的研究方向：医学;生命科学
经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。

217 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2022-03-15 ms5000000502998946

审稿速度:1.0 | 投稿命中率:75.0
经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。
目前是5200刀版面费。0119-0221期间，一直是under consideration状态。

64 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2177037, encodeId=37e221e703740, content=偏重的研究方向：医学基础 经验分享： 8.5 submit 8.20 with editor 8.22 under review 10.17 major review 12.4 R1 submit 12.6 under review 12.22 accept , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=122d6402174, createdName=ms3000001060797325, createdTime=Mon Dec 25 11:11:44 CST 2023, time=2023-12-25, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2094661, encodeId=75c3209466178, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：能源;材料 经验分享：9.10投稿 9.13with editor 9.21送审 10.4大修 2个审稿人主编给了20天时间修改 10.12提交修改稿 10.19接收 17年投过一次AS，当时AM送审后投的，也是10月份左右投稿的，投稿号只有700多，但没送审。这次是投AM转投的，主编给了送审的机会，审稿人回复意见很快，2个审稿人提了6条意见，几乎不需要补实验，也可能是我做的比较全（支撑信息70页），运气比较好，总共一个多月就接收了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3d1e5693028, createdName=ms8000000233807128, createdTime=Wed Oct 19 09:22:38 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140532, encodeId=d916214053222, content=偏重的研究方向：医学;免疫;肿瘤 经验分享：5-24 submitted, 1周了还没变化，后悔死了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7de85684843, createdName=ms7000001335611101, createdTime=Fri Jun 02 20:46:21 CST 2023, time=2023-06-02, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2152429, encodeId=0e0e2152429be, content=这个期刊和大CDD比起来怎么样啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sat Aug 12 15:19:59 CST 2023, time=2023-08-12, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2106109, encodeId=f86d2106109a4, content=12-7submitted，一直到今天都没有变化，是凉凉了嘛？生命科学方向的胃肠单细胞, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=92, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d39f6490357, createdName=ms6000000798925478, createdTime=Wed Dec 14 23:13:02 CST 2022, time=2022-12-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2110536, encodeId=3f6b21105360a, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：我服了，一审大修返回去现在一个半月了没消息，搞什么啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71d66566285, createdName=ms5000001185631738, createdTime=Tue Jan 17 09:56:40 CST 2023, time=2023-01-17, status=1, ipAttribution=东京都), GetPortalCommentsPageByObjectIdResponse(id=2143513, encodeId=196121435130d, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：医学;生物材料 经验分享：6.11 submitted 6.13 with editor 6.18 under review 前面有前辈说从投稿到给意见都是under consideration，为什么不一样呢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9cae5572422, createdName=食野-, createdTime=Sun Jun 18 17:26:34 CST 2023, time=2023-06-18, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2128189, encodeId=f7bb2128189b3, content=偏重的研究方向：医学;生命科学 经验分享：生物医学类的，着急毕业的千万千万慎重投这个，submit状态等了两周才到editor那里，白白浪费两周时间，切记，慎投。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7ec8220098, createdName=ms9000001428733424, createdTime=Tue Apr 25 09:34:16 CST 2023, time=2023-04-25, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=1202686, encodeId=a4e11202686ac, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：2022年1月19日提交。2月21日审稿意见出来，给10天时间修改。3月3日提交回复审稿意见。3月8日接收。 目前是5200刀版面费。0119-0221期间，一直是under consideration状态。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ffe6552622, createdName=ms5000000502998946, createdTime=Tue Mar 15 09:51:06 CST 2022, time=2022-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177868, encodeId=9ee021e786883, content=偏重的研究方向：医学;医学基础 经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98915615415, createdName=ms1000000907051820, createdTime=Thu Dec 28 21:38:54 CST 2023, time=2023-12-28, status=1, ipAttribution=河南省)]

2023-12-28 ms1000000907051820 来自河南省

偏重的研究方向：医学;医学基础
经验分享：8.10 submit 9.27 一审修回 10.19 一审提交 11.30 accept 12.25 online 感谢审稿人和编辑部的高效率，很顺利的一次投稿。终于有了第一篇代表作。继续努力💪

101 10

展开10条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务